Genentech files Avastin for new brain cancer use
This article was originally published in Scrip
Executive Summary
Genentechhas filed its anti-VEGF monoclonal antibody Avastin (bevacizumab) in the US for use in patients with previously treated glioblastoma. The supplemental BLA is eligible for accelerated review based on preliminary evidence suggesting a clinical benefit for this aggressive cancer, and is based on data from the Phase II BRAIN study reported at ASCO earlier this year.